Tech Company Financing Transactions
Traversa Therapeutics Funding Round
Traversa Therapeutics secured a $5 million venture capital round on 4/2/2009. Investors included Mesa Verde Venture Partners, Morningside Group and private investors.
Transaction Overview
Company Name
Announced On
4/2/2009
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Undisclosed
Investors
Mesa Verde Venture Partners (Daniel Wood)
Morningside Group (Isaac Cheng)
Proceeds Purpose
Proceeds from the investment will support the advancement of Traversa's RNAi oncology programs into clinical trials.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
10480 Wateridge Circle
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Not Recorded
Overview
Traversa Therapeutics, Inc. is a La Jolla, California-based biopharmaceutical company engaged in the discovery, development and commercialization of RNAi delivery technologies. The company strives to rapidly advance siRNA platform delivery technologies for use internally and by other pharmaceutical companies in targeting a wide variety of acute, chronic and infectious human diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Scientific Officer
Curt Bradshaw
Founder
Steven Dowdy
Browse more venture capital transactions:
Prev: 4/2/2009: Onehub venture capital transaction
Next: 4/2/2009: Swoopo venture capital transaction
Share this article
Where The Data Comes From
We record all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs